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Abstract
Background: Cardiac rehabilitation (CR) is an essential component of contemporary management for patients with
coronary heart disease, including following an acute coronary syndrome (ACS). CR typically involves education and
support to assist people following an ACS to make lifestyle changes and prevent subsequent events. Despite its
benefits, uptake and participation in tradition CR programs is low. The use of mobile technologies (mHealth) offers
the potential to improve reach, access, and delivery of CR support. We aim to determine the effectiveness and
cost-effectiveness of a text-messaging intervention (Text4Heart II) to improve adherence to medication and lifestyle
change in addition to usual care in people following an ACS. A second aim is to use the RE-AIM framework to
inform the potential implementation of Text4Heart II within health services in New Zealand.
Methods: Text4Heart II is a two-arm, parallel, superiority randomized controlled trial conducted in two large
metropolitan hospitals in Auckland, New Zealand. Three hundred and thirty participants will be randomized to
either a 24-week theory- and evidence-based personalized text message program to support self-management in
addition to usual CR, or usual CR alone (control). Outcomes are assessed at 6 and 12 months. The primary outcome
is the proportion of participants adhering to medication at 6 months as measured by dispensed records. Secondary
outcomes include medication adherence at 12 months, the proportion of participants adhering to self-reported
healthy behaviors (physical activity, fruit and vegetable consumption, moderating alcohol intake and smoking status)
measured using a composite health behavior score, self-reported medication adherence, cardiovascular risk factors
(lipids, blood pressure), readmissions and related hospital events at 6 and 12 months. A cost-effectiveness analysis will
also be conducted. Using the RE-AIM framework, we will determine uptake and sustainability of the intervention.
Discussion: The Text4Heart II trial will determine the effectiveness of a text-messaging intervention to improve
adherence to medication and lifestyle behaviors at both 6 and 12 months. Using the RE-AIM framework this trial will
provide much needed data and insight into the potential implementation of Text4Heart II. This trial addresses many
limitations/criticisms of previous mHealth trials; it builds on our Text4Heart pilot trial, it is adequately powered, has
sufficient duration to elicit behavior change, and the follow-up assessments (6 and 12 months) are long enough to
determine the sustained effect of the intervention.
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Background
Cardiovascular diseases (CVD) are the leading causes of
premature death and disability worldwide, accounting
for 30% of all global deaths [1]. By 2030, almost 23.6
million people will die from CVD, mainly coronary heart
disease (CHD), and the total number of disability-
adjusted life years attributable to CVD is expected to
reach approximately 204 million [1]. People with CVD
are more likely to develop future cardiac events such as
unstable angina, myocardial infarction (MI), and sudden
cardiac death [2]. This places a huge burden on health-
care systems, with the US spending US$444 billion on
CVD-related treatments in 2010 [3].
Improved diagnosis, treatment, and management have
substantially reduced the mortality rate of individuals
living with CHD [4, 5]; however, those who have experi-
enced an MI have a 20–40% risk of a recurrent event or
death in the next 5 years [4, 5]. Approximately 80% of
CHD is caused by modifiable risk factors including phys-
ical inactivity, smoking, unhealthy diet, and harmful
alcohol consumption [6], and effective evidence-based
secondary prevention treatments—such as implementing
lifestyle changes and adhering to prescribed medication
regimens (self-management)—can aid recovery and
reduce recurrent cardiac events. Improvements in lipids,
systolic blood pressure, smoking prevalence, and phys-
ical activity account for an estimated 47% of the total
improvement in case fatality [5].
Management of CHD
Acute coronary syndrome (ACS) encompasses unstable
angina, and MI. Following diagnosis of an ACS, patients
should receive a range of evidence-based preventive
treatments that include appropriate clinical follow-up, as
well as referral to programs that provide education and
support self-management for the secondary prevention
of disease—commonly known as cardiac rehabilitation
(CR). A core focus of CR is to encourage people to make
healthy lifestyle changes to reduce subsequent cardiac
events. Lifestyle behavior changes include regular phys-
ical activity, eating a healthy diet, stopping smoking, re-
ducing harmful alcohol intake, and taking medications as
per a prescribed regimen [7]. Empowering self-management
is critical for people with an ACS to maximize treatment
benefits [8].
CR is an essential part of contemporary management
for people with an ACS. It has been shown to reduce
cardiovascular deaths and hospital readmissions by 25%
[7], and is cost-effective for those who participate [9]. A
Cochrane systematic review [10] of CR reported a statisti-
cally significant reduction in cardiovascular mortality of
26% (odds ratio (OR) 0.74, 95% CI 0.57 to 0.96) and a
reduction in all-cause mortality of 13% (OR 0.87, 95%
confidence interval (CI) 0.71 to 1.05). This magnitude of
effect is consistent with a review of cohort studies and
randomized controlled trials (RCTs) [11].
Despite these benefits, CR participation is inadequate
in all countries in which it has been assessed [12]. Low
levels of patient participation and completion (14–43%
after MI) have been reported in Australia, France, the
United Kingdom, and New Zealand with high levels of
dropout after enrollment [13–17]. Lack of completion
reduces the benefits of CR, such as improvements in
CVD risk factors [18]. Patient-oriented, medical, and
healthcare system factors associated with suboptimal
participation include availability, affordability and acces-
sibility of a program, as well as work/domestic commit-
ments and psychological barriers [19, 20]. Current CR
delivery approaches do not suit all people and new
models are needed to improve the uptake and comple-
tion of CR. A range of options should be available for
people according to their preferences and needs [21].
New approaches to enhance self-management
A recent systematic review of alternative models of care
found multifactorial individualized telehealth and com-
munity- or home-based CR were effective alternatives as
they have produced similar reductions in CVD risk factors
compared with hospital-based programs [22]. This echoes
findings from other reviews of home-based CR [23] and tel-
ehealth [24]. There is a paucity of research describing the
effectiveness of alternative models of CR in rural, remote,
and culturally diverse populations. However, evidence sug-
gests that hospital-based strategies may not be able to de-
liver effective CR to these populations. Local healthcare
systems may need to integrate alternative models of CR,
such as brief interventions tailored to individual’s risk factor
profiles, as well as community- or home-based programs,
to ensure that choices are available that best fit patient’s
needs, risk factor profile, and preferences.
The potential of mobile phone delivered self-management
While telehealth [24] and Internet-based programs have
been shown to be effective, they are limited due to
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predominant reliance on desktop and landline communi-
cation, whereas technology is now more mobile. Mobile
phones are the most common device for communication
worldwide—including developing countries—and are used
to deliver behavioral-change programs and improve
disease self-management [25]. Mobile phones have poten-
tial to influence behavior at a population level because the
technology is widely available globally, inexpensive, and
allows instant delivery of information [26].
Text-messaging—or short message service (SMS)—is
the most widely used mobile phone intervention. Two
systematic reviews [27, 28] support the effectiveness of
SMS interventions across a range of risk behaviors (e.g.,
smoking) and chronic conditions (e.g., diabetes and
asthma). A 24-week text-messaging intervention in the
HEART trial increased walking and leisure time exercise
in people who were post ACS (n = 171), but did not
increase maximal exercise capacity [29, 30]. The TEXT
ME trial—which is the largest trial in people with CVD
(n = 710) [31]—reported statistically significant positive
effects on low-density lipoprotein (LDL) cholesterol, and
sizeable effects on secondary outcomes such as blood
pressure and physical activity. This intervention involved
delivery of regular semi-personalized text messages pro-
viding advice, motivation, and information that aimed to
improve diet, increase physical activity, and encourage
smoking cessation. While this study represents a good
initial evaluation of a text messaging intervention for en-
hancing CHD outcomes, future work is still required.
First, it was conducted in a single center in Australia with
many participants excluded due to language barriers or not
owning a mobile phone, which limits its generalizability.
Second, the intervention was evaluated as a stand-alone
strategy, thus it was unclear whether the intervention was
more or less beneficial to those in traditional programs.
Third, implementation of the intervention in a real-world
setting was not assessed in the study.
We previously conducted the Text4Heart randomized
controlled pilot trial (n = 123) [32, 33], of a 6-month
theory-based program of daily text messages and a sup-
porting website in addition to usual CR services. Using a
composite measure of lifestyle change (exercise, diet,
smoking, alcohol), we observed a significant treatment
effect on adherence to lifestyle behaviors at 3 months
(adjusted OR = 2.55, 95% CI 1.12 to 5.84; p = .03), but not
at 6 months (adjusted OR = 1.93, 95% CI 0.83 to 4.53; p
= .13). At 6 months, the intervention group had greater
self-reported medication adherence (mean difference in
scores: 0.58, 95% CI 0.19 to 0.97; p = .004), with 51%
reporting high adherence compared to 32% in the control
condition. Text4Heart was also associated with lowered
LDL cholesterol at 6 months compared with control
(mean difference: − 0.25, 95% CI -0.49 to 0.003; p = .05).
Participants reported high fidelity to the text-message
component of the intervention, with 85% of intervention
participants reading all their messages. Text4Heart was
well-received with 84% of participants reporting that the
program helped them recover, and 90% of participants
would have recommended it to others who had a cardiac
event [33]. A definitive trial of Text4Heart to determine
its effectiveness using an objective measure is now
required to determine the sustained effect of the interven-
tion for augmenting existing cardiovascular services.
Aims
To determine the effectiveness and cost-effectiveness of
the Text4Heart II self-management program—in
addition to usual care—to improve adherence to medica-
tion and lifestyle change in people with an ACS. A sec-
ond aim is to use the RE-AIM framework [34] to inform
the potential implementation of the Text4Heart II pro-
gram to augment existing CR services with two district
health boards in Auckland, New Zealand.
Hypotheses
1. Text4Heart II will improve self-management of ACS,
as seen by increased adherence to medication and
lifestyle behaviors at 6 and 12 months compared to
standard CR care alone,
2. Text4Heart II will be cost-effective, and
3. Text4Heart II will be imminently scalable for roll
out within the existing healthcare system in New
Zealand (district health boards)
Methods
The Text4Heart II trial is a two-arm, parallel, super-
iority RCT conducted in two large metropolitan hos-
pitals in Auckland, New Zealand. The study protocol
is in accord with the Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) 2013
Statement [35], and was prospectively registered in
the Australian New Zealand Clinical Trials Registry
on 1 April 2016, (ACTRN12616000422426). The
intervention is described according to the Consoli-
dated Standards of Reporting Trials (CONSORT)-
eHealth Checklist [36]. The trial schedule is presented
in Fig. 1, and the SPIRIT Checklist is reported in
Additional file 1.
Study population and recruitment
Adults who are clinically stable, able to read English,
and provide informed consent are invited to participate
into the study either while inpatients, or shortly after
discharge following ACS or post percutaneous coronary
intervention. Exclusion criteria include untreated ven-
tricular tachycardia, severe heart failure, life-threatening
co-existing disease with life expectancy below 1 year, and
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significant exercise limitations other than CVD. Potential
participants will be given information sheets by a re-
searcher and informed consent will be obtained either in
writing, or verbally if the participant is already discharged.
All patients admitted with ACS or who undergo angi-
ography are registered in the All New Zealand Acute
Coronary Syndrome Quality Improvement register (AN-
ZACS-QI) [37]. ANZACS-QI collects detailed informa-
tion on risk factors, diagnosis, investigations, as well as
management and complications during admission, and is
embedded in > 90% of hospitals in New Zealand. Data
are able to be linked to laboratory results and dispensing
from chemists. Anonymized linkage to patients’ unique
National Health Index number allows data to be ob-
tained on mortality and rehospitalization for subsequent
analysis [38]. This study design, utilizing the strengths of
the clinical registry combined with the specific clinical
trial protocol, provides a unique opportunity to collect
study data at low cost and with no additional participant
burden.
Sample size
A total of 330 participants (165 per group) will provide
80% power at the 5% level of significance (two-sided) to
detect an absolute difference of 15% between the two
groups, in the proportions of participants adherent to
medication 6 months after randomization (assuming a
control rate of 30%). This is a conservative control rate
and is based on our self-reported Text4Heart pilot data,
and New Zealand research that found only 60% of pa-
tients had a Medication Dispensing Ratio (SDR) > 0.8
for statins only [39]. This value is likely to be lower
when all classes of medication (statins, antihyperten-
sive, and antiplatelet therapies) are considered. If the
control rate was indeed 60% then a total of 304 partici-
pants would be required to detect an absolute difference
of 15%; thus, we would be adequately powered with our
proposed sample size.
Randomization, allocation concealment, and blinding
Upon completion of baseline assessment a researcher
will randomly allocate eligible participants at a 1:1 ratio
to the intervention or control arm, using blocked (vari-
able block sizes, 2 or 4) stratified (hospital site)
randomization. The allocation sequence will be com-
puter generated by an independent statistician not in-
volved with trial conduct, and concealed by a centralized
computer system that will reveal treatment allocation
only after submission of baseline data. Study investiga-
tors (but not participants) are blinded to intervention
allocation throughout the trial. The primary outcome,
however, is derived from data linkage, which is blind to
treatment allocation.
Fig. 1 Schedule of enrollment, interventions, and assessments (Standard Protocol Items: Recommendations for Interventional Trials
(SPIRIT) Figure)
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Intervention and control
All participants will receive usual care, which includes
CR support. In addition, those allocated to the
Text4Heart II intervention arm will receive a personal-
ized, automated program of CR delivered via text mes-
sage over 24 weeks. The overall goals of the intervention
are to encourage and promote adherence to medication,
healthy diet, stress management, regular exercise,
reduced alcohol consumption, and smoking cessation (if
applicable). Participants will be able choose additional
focussed intervention modules at baseline that address
risk factors that they identify as most relevant to them,
such as physical activity, heart healthy diet, stress man-
agement, and smoking cessation.
Participants receive one message per day for the first
12 weeks, a technical support phone call at 12 weeks,
and five messages per week for the remaining 12 weeks.
Messages will be personalized (including participants’
names) and sent at times to suit participants. The inter-
vention is predominantly unidirectional but participants
will be able to reply to text messages and a researcher
will answer within 24 h. All participants will be offered
brief training at enrollment on how to read, delete, and
save text messages. Messages are categorized into four
groups (see below). Non-smokers receive one to two
general heart health messages, one to two physical activ-
ity messages, and one to two dietary messages per week.
Smokers receive one general heart health message, one
to two physical activity messages, one to two dietary
messages, and one to two smoking-cessation support
messages per week.
At registration, intervention group participants will
select their preferred receipt times for educational (early
morning, late morning, early afternoon, late afternoon,
or evening) and medication reminder messages to
ensure that the timing is appropriate for their needs.
Details of the text-message content are provided below.
Intervention content
General heart health and medication adherence
General health information messages that include facts
about risk factors and medication will be provided. Mes-
sages will include information and strategies to help par-
ticipants adhere to their prescribed medication
regimen—including information on the value of taking
medication to reduce recurrent events and hospitalization,
reminders to have a regular check-up with their physician,
enhancing self-management, and addressing illness
perceptions and medications beliefs. In addition, advice
will be given about contacting their physician if unwell,
practical tips on how to improve lifestyle though habit for-
mation and environmental prompts, and how to enlist
support from others.
Physical activity
Participants will receive messages derived from the
successful HEART trial [29, 30], that address the import-
ance of being physically active. Message content will
include suggested activities, key strategies to enhance
uptake and maintenance of physical activity (e.g., goal
setting, self-monitoring), and a generic exercise prescrip-
tion that suggests the type, frequency, duration, and
intensity of exercise.
Dietary behavior
Participants will be supported to reduce dietary saturated
fat and salt intake, and to manage their weight. All content
was developed, pre-tested and successfully piloted prior to
the Text4Heart II trial [40]. Participants will receive text
messages promoting healthy eating strategies, advice on
choosing healthy food, and food preparation. The
messages focus on supporting behavior-change strategies.
Smoking cessation
Participants who smoke tobacco will receive compo-
nents of the successful STOMP text-messaging
smoking-cessation intervention [41–43]. They will be
sent regular messages providing smoking-cessation ad-
vice and support (e.g., symptoms to expect on quitting,
tips to avoid weight gain and to cope with craving, ad-
vice on avoiding smoking triggers).
All messages are grounded in established psychological
(Common Sense Model) [44] and behavior-change
(Social Cognitive) theory [45] and will focus on modify-
ing perceptions of the symptoms, timeline, causes, con-
sequences, understanding of, personal control over, and
ability of treatment to prevent, CVD [46], as well as
altering the key mediators of behavior change including
self-efficacy, social support, and motivation.
Outcomes
All outcomes are assessed at 6 and 12 months post
randomization. The primary outcome is the proportion
of participants adhering to medication at 6 months.
Medication adherence is defined as SDRs of 80% for sta-
tins, antihypertensive, and antiplatelet therapy classes of
medication (calculated separately)—consistent with
guideline-recommended therapy [47]—where SDR is
calculated as the number of days that the supply is ob-
tained divided by the number of days in the observation
period. Participants’ community pharmacy dispensing
records will be linked using their unique National Health
Index number via the National Pharmaceuticals Collec-
tion database. This approach has been used successfully
in New Zealand to assess statin use [39]. To adjust for
days not covered due to death or days spent in hospital
these periods are subtracted from the 6-month coverage
time. The number of days supplied will be estimated
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from strength per unit and daily dose variables summed
from pharmacy claims during the observation period. To
account for any previous supply of the medication
(before discharge), medication claims in the 3 months
prior to admission are collected. The SDR for each class
of medication (statins, antihypertensive, and antiplatelet
therapies) will be recorded as secondary outcomes.
Secondary outcomes
In a similar manner to the primary outcome, the propor-
tion of participants adhering to medication will be
assessed at 12 months. Self-reported outcomes will be
measured by a trained research assistant during a tele-
phone call at 6 and 12 months. Self-reported medication
adherence will be assessed using the Morisky 8-item
Medication Adherence Scale [48]. As per the Text4Heart
pilot trial [32, 33], adherence to recommended lifestyle
behaviors will be measured using a composite health be-
havior score adapted from the EPIC-Norfolk Prospective
Population Study [49]. The following measures will be
used to determine participants’ health behavior scores:
1. Smoking status will be measured using three items
from a validated smoking history questionnaire [50]
including whether participants have ever smoked,
have had a puff of tobacco in the last week and
when they quit smoking (if appropriate)
2. Physical activity level will be assessed using the
Godin Leisure Time Physical Activity Questionnaire
(GLTPAQ) [51]. This simple, three-item question-
naire has well-established reliability and validity and
has been used in patients undergoing CR
3. Alcohol consumption will be measured using the
Alcohol Use Disorders Identification Test alcohol
consumption questions (AUDIT-C) [52]—a
screening tool designed to assess units of alcohol
consumed per week, and identify people who are
hazardous drinkers. Index cards referencing standard
drink sizes will be used to reduce comprehension
errors
4. Fruit and vegetable intake are assessed by two New
Zealand-specific questions used in the 2006/2007
New Zealand Health Survey (n = 12,488, including
adults with CHD) [53]
Participants receive a score on a 4-point scale for each
of the four key risk factors, with 1 point each assigned
for being a current non-smoker, meeting physical activity
guidelines to achieve some health benefits (defined as ≥
14 units on the GLTPAQ), consuming ≤ 14 standard
units of alcohol per week, and consuming at least five
servings of fruit and vegetables per typical day.
Using participants’ encrypted National Health Index
identification numbers we will be able to obtain clinical
data (lipid profiles and blood pressure) from the
ANZACS-QI database to maximize collection of these
outcomes. Data describing hospital events, clinical infor-
mation, as well as medication prescribing and dispensing
will also be captured. For the purpose of this trial we will
access data on lipid profile (total/LDL/HDL cholesterol)
and blood pressure, from admission and routine follow-
ups. Using ANZACS-QI we will also be able to access
information on readmissions and related hospital events.
Intervention delivery costs—including text-message
service and per message costs as well as health service
staff time for recruitment and program facilitation—will
be collected. Any changes in health service utilization
observed between intervention and control groups will
lead to an estimation of the costs of those changes with
the assistance of District Health Board funding informa-
tion analysts.
Adverse events
All participants will continue with their usual care for
ACS. No individual clinical advice is given through the
pre-programmed text messages. We will be evaluating
hospitalizations or health service utilization as part of
the outcomes specified above.
Statistical analysis
Trial data collected from all eligible participants will be
linked with the national ANZACS-QI database using
participants’ encrypted National Health Index number
for the purpose of analysis. Treatment evaluations will
be performed on the principle of intention-to-treat
(ITT). Missing data on the primary outcome will be con-
sidered as non-adherence in the ITT approach. Sensitiv-
ity analyses will be conducted to test the robustness of
main findings using different assumptions on the miss-
ing data if the proportion of missing exceeds 10%. The
proportion of participants adhering to medication at
6 months, with or without intervention, will first be
summarized as frequency and percentage. Logistic
regression will be conducted to evaluate the main treat-
ment effect (OR and 95% CI), adjusting for pre-defined
baseline prognostic factors. For all secondary outcomes
collected at 6 and 12 months post randomization, gener-
alized linear regression models will be used to test the
effect of intervention between two groups, using a link
function appropriate to the distribution of outcomes.
More specifically, an identity link will be used for con-
tinuous outcomes under normal distribution and a logit
link for binary outcomes under binomial distribution.
Regression models will adjust for baseline outcome value
(where collected) and stratification factor. Model-
adjusted estimate (mean difference for continuous out-
comes and OR for binary outcomes) will be reported at
each scheduled visit, with 95% CI and associated p value.
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Missing data will not be imputed on secondary out-
comes without adjustment for multiple testing. Statis-
tical analysis will be performed using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA). All statistical tests
will be two-sided at the 5% significance level.
Cost-effectiveness analysis
This analysis will adopt a health system perspective. We
will use the EQ-5D—a generic and validated measure of
quality of life for which reliable New Zealand population
preference values are available—to obtain a single prefer-
ence index for calculation of Quality-adjusted life-years
(QALYs) to assess cost per QALY, for comparison with
other programs. The incremental cost of making one extra
participant adherent to CR using the intervention com-
pared to usual care will be calculated. Ninety-five percent
confidence intervals for incremental cost-effectiveness
ratios, 95% confidence ellipses on the incremental cost-
effectiveness plane, and cost-effectiveness acceptability
curves will be calculated to compare the intervention with
usual care. Markov modeling will combine these data with
other information from a systematic review of cost-
effectiveness studies of CR to identify the long-term cost-
effectiveness of the intervention.
Data management
Data will be entered into an electronic collection system
provided by Enigma Solutions which will be linked to
the ANZACS-QI register. Range checks will be imple-
mented and 10% of data will be checked for consistency
against source data.
Evaluating implementation
We propose using the RE-AIM model proposed by Glas-
gow and colleagues [34, 54] to determine uptake and
sustainability of the intervention. The RE-AIM frame-
work—which emphasizes collecting information about
the Reach, Effectiveness, Adoption, Implementation, and
Maintenance of an intervention—is an evaluative frame-
work for guiding the evaluation and reporting of health
intervention effectiveness [55]. Further, RE-AIM pro-
vides a framework for determining which programs
work under real-world conditions and which programs
should be sustained. The RE-AIM framework is an ideal
tool to use as the basis for planning and evaluating the
success of mobile phone self-management interventions
[56, 57]. It also aligns with systems-based approaches
and allows for assessment of vertical (e.g., adoption deci-
sions within a given organization) and horizontal (e.g.,
adoption across different sectors) components [58]. The
RE-AIM framework includes both individual- and set-
ting/staff-level variables. Two dimensions operate at the
individual level (reach and effectiveness).
A mixed-methods approach [59] will be used to assess
the key components of RE-AIM. Qualitative and quanti-
tative data will be combined to thoroughly understand
the extent to which the self-management intervention
could be successfully implemented within the New
Zealand health context [60]. To achieve this, data will be
collected on each RE-AIM dimension as proposed by
Kessler et al. [61] and Glasgow [60]. Some of these data
will be collected as part of the trial (e.g., data to inform
reach, effectiveness and costs/resources). Additional data
will be collected specifically for the RE-AIM analysis
(detailed below).
To determine intervention reach, we will assess the
number of people who participate as a proportion of those
who are eligible, compare the characteristics of those who
do and do not participate, and provide detailed informa-
tion of reach and recruitment issues [62, 63]. To achieve
this, all potential participants approached about the study
will be screened and basic information collected. Those
who decline participation will have their information per-
manently de-identified. Screening information will be used
to determine the representativeness of those who agree to
participate compared to those who decline. Qualitative
data will be gathered from those who decline about their
reasons for choosing to not participate. For those who
agree, a brief semi-structured interview will be conducted
to determine their perspectives of the proposed interven-
tion, their current self-management behaviors, and any
concerns they might have that would have impacted on
their involvement or adoption.
In addition to the primary outcome, biological-, psy-
chosocial-, demographic-, and program-specific parame-
ters will be assessed as potential moderators of
intervention effectiveness.
RE-AIM dimensions Adoption, Implementation, and
Maintenance will be assessed from both provider and
organizational perspectives [54]. Key informant inter-
views will be conducted with stakeholders (medical prac-
titioners and allied health staff ) to obtain qualitative
data from providers across these three RE-AIM dimen-
sions, to determine factors that may enhance
organizational adoption and maintenance, and potential
adaptations to heighten the likelihood of consistent de-
livery across providers and locations. Quantitative
assessment of implementation will be determined by
measuring text-message responses where appropriate.
Maintenance at the organizational level will be deter-
mined by conducting key informant interviews with
stakeholders (e.g., chief executive officers) as well as gov-
ernment and non-government agencies (Ministry of
Health, Heart Foundation) examining potential sustain-
ability options for each organization [64]. To evaluate
Maintenance at the patient level, patient outcomes will
be measured at 12 months via ANZACS-QI. Long-term
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attrition (%) and differential rates by patient characteris-
tics or treatment condition will be examined. At the
organizational level, we will collect data on whether the
interventions were sustained at more than 6 months
post study funding, or which elements were retained
after the program was funded.
Qualitative data collection and analysis will be con-
ducted by a trained and experienced researcher. Inter-
views will be digitally recorded and transcribed. Data
will be entered using NVivo software to enable qualita-
tive analysis. An inductive analysis approach will be used
to identify the key themes to emerge from the data.
These data will be collated according to each domain of
the RE-AIM framework. These data sources will be com-
bined and—together with the advisory group—investiga-
tors will make recommendations to determine the
extent to which the self-management intervention
achieved the desired RE-AIM outcomes. This approach
has been successfully used with other behavior-change
interventions and will also be valuable for informing
optimal scenarios for funding and implementing this
self-management program [54, 65, 66].
Discussion
The Text4Heart II trial will determine the effectiveness
of a text-message-based intervention in addition to usual
care for improving adherence to medication and lifestyle
behaviors at both 6 and 12 months. Using the RE-AIM
framework this trial will provide much needed data and
insight into the potential implementation of Text4Heart
II to augment existing cardiac services within two major
metropolitan hospitals. The protocol, in accordance with
the SPIRIT Statement, includes outcomes from recent
systematic reviews of mobile health with the aim of add-
ing quality evidence to the body of academic literature.
This trial addresses many limitations/criticisms of pre-
vious mHealth trials [43, 67]; it builds on the Text4Heart
pilot trial, is adequately powered, has sufficient duration
to elicit behavior change, and the follow-up assessments
(6 and 12 months) are long enough to determine the
sustained effect of the intervention. We also outline the
behavior-change theory used, and intervention content,
which will enhance its replicability. Using data linkage
(National Pharmaceuticals Collection and ANZACS-QI
registries) our Text4Heart II trial will not only provide
an objective measurement of medication adherence, but
will be one of the first of its kind to provide much
needed data on sustained effects on clinical outcomes
including hospitalization and mortality. While mHealth
is often touted as a low-cost intervention that can be de-
livered at scale, few studies provide evidence of this. The
Text4Heart II trial will also provide much needed data
on the cost-effectiveness of this approach, and its poten-
tial implementation and scalability as a national service.
In summary, Text4Heart II should produce new know-
ledge on the effectiveness and cost-effectiveness of an
innovative and promising mHealth program to improve
self-management of heart disease. It extends previous
research by investigating the sustained effects of a text-
message intervention, and will offer unique insights into
clinical effects. If effective, this approach could substan-
tially reduce deaths and hospital admissions in a group
of patients who account for up to one third of all hos-
pital admissions. We will provide much needed insight
into the potential of implementing this program at a
national level, thereby augmenting existing CVD service
delivery.
Trial status
Recruitment for the Text4Heart II trial opened in July
2016 at Auckland City and North Shore Hospitals
(Auckland, New Zealand). Recruitment is currently
open, and expected to be completed in October 2017.
The original study protocol was finalized on 18 March
2016; this manuscript reports version 5, amended on 13
December 2016. The primary amendment extended
follow-up to 12 months, facilitated by an award from
National Heart Foundation of New Zealand. Version
control has been implemented to document all amend-
ments to the study protocol, and these will be communi-
cated to the Ethics Committees and trial investigators as
required.
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